Apolipoprotein E, amyloid-β, and blood-brain barrier permeability in Alzheimer disease
Journal of Neuropathology and Experimental Neurology, ISSN: 0022-3069, Vol: 67, Issue: 4, Page: 261-270
2008
- 86Citations
- 105Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations86
- Citation Indexes86
- 86
- CrossRef54
- Captures105
- Readers105
- 98
Review Description
There is increasing evidence for blood-brain barrier (BBB) compromise in Alzheimer disease (AD). The presence of the ε4 allele of the apolipoprotein E (apoE) gene is a risk factor for sporadic AD. Apolipoprotein E is essential both for maintenance of BBB integrity and for the deposition of fibrillar amyloid-β (Aβ) that leads to the development of Aβ plaques in AD and to cerebral amyloid angiopathy. This review investigates the relationships between apoE, Aβ, and the BBB in AD. Alterations in the expression and distribution of the BBB Aβ transporters receptor for advanced glycation end-products and low-density lipoprotein receptor-related protein 1 in AD and the potential roles of apoE4 expression in adversely influencing Aβ burden and BBB permeability are also examined. Because both apoE and Aβ are ligands for low-density lipoprotein receptor-related protein 1, all 3 molecules are present in AD plaques, and most AD plaques are located close to the cerebral microvasculature. The interactions of these molecules at the BBB likely influence metabolism and clearance of Aβ and contribute to AD pathogenesis. Therapeutic alternatives targeting apoE/Aβ and sealing a compromised BBB are under development for the treatment of AD. © 2008 American Association of Neuropathologists, Inc.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=41949101345&origin=inward; http://dx.doi.org/10.1097/nen.0b013e31816a0dc8; http://www.ncbi.nlm.nih.gov/pubmed/18379441; https://academic.oup.com/jnen/article-lookup/doi/10.1097/NEN.0b013e31816a0dc8; https://dx.doi.org/10.1097/nen.0b013e31816a0dc8; https://academic.oup.com/jnen/article/67/4/261/2916878
Oxford University Press (OUP)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know